Viracta Therapeutics Inc. (VIRX)
0.02
-0.00 (-6.54%)
At close: Apr 04, 2025, 3:28 PM
-6.54% (1D)
| Bid | 0.02 |
| Market Cap | 874.37K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.4 |
| Analyst | Buy |
| Ask | 0.03 |
| Volume | 19,199 |
| Avg. Volume (20D) | 919,268 |
| Open | 0.02 |
| Previous Close | 0.02 |
| Day's Range | 0.02 - 0.02 |
| 52-Week Range | 0.01 - 1.31 |
| Beta | 0.23 |
About VIRX
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as we...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2005
Employees 26
Stock Exchange OTC
Ticker Symbol VIRX
Website https://www.viracta.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VIRX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 13536.36% from the latest price.
Stock Forecasts7 months ago
-11.76%
Viracta Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
